Drugs / interferon alfa-2b
interferon alfa-2b
also known as
Interferon alpha-2b · Intron A · IFN-α-2b · IFN-A2b · IFN-alpha2b · HDI · IFN alfa-2b · IFN-A · +13 more
Regulatory milestones approvals, filings & regulatory actions · 10 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Withdrawn | EU (EMA) | Viraferon | — | 2008-10-13 | europa.eu ↗ |
| Label expansions (7) | US (FDA) | INTRON A | — | 1992-07-13 – 2001-06-21 | fda.gov ↗ |
| Approved | EU (EMA) | IntronA | — | 2000-03-09 | europa.eu ↗ |
| Approved | US (FDA) | INTRON A | — | 1986-06-04 | fda.gov ↗ |
Trials 72 · started per year
today
US approved 1986
EU approved 2000
1
1
6
1
5
3
5
6
2
2
1
5
6
8
2
3
1
2
4
1
2
1
1
1
1986198719881989199019911992199319941995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 03 trials | ||||||
| Phase 0 | NCT07635459 | Jul 2026 → Jun 2027 expected | chronic rhinosinusitis | The First Affiliated Hospital of Xinxiang Medical College | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT02331706 | Dec 2014 → Nov 2016 | leukemia | Abramson Cancer Center at Penn Medicine | Completed | No outcome recorded |
| Phase 0 | NCT00871533 | Sep 2009 → Aug 2017 | melanoma | University of Pittsburgh | Terminated | No outcome recorded |
| Phase 111 trials · 1 met primary | ||||||
| Phase 1 | NCT03056599 | Dec 2016 → Jul 2021 | soft tissue sarcoma | Presage Biosciences | Completed | Met primary |
| Phase 1 | NCT02781753 | Apr → Aug 2016 | — | Tianjin SinoBiotech Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT02339324 | Mar 2015 → Sep 2019 | melanoma | Yana Najjar | Completed | No outcome recorded |
| Phase 1 | NCT02174172 | Aug 2014 → Nov 2019 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT01217359 | May 2010 → Aug 2012 | hepatitis C virus infection | University of North Carolina, Chapel Hill | Completed | No outcome recorded |
| Phase 1 | NCT00970996 | Sep 2009 → Dec 2012 | melanoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT00629200 | Sep 2006 → Feb 2010 | cancer of unknown primary site | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT00908869 | May 2006 → May 2010 | neoplasm | Institut Paoli-Calmettes | Completed | No outcome recorded |
| Phase 1 | NCT01462773 | Jan 2006 → Oct 2010 | melanoma | Ohio State University Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT00001035 | ? → Sep 1996 | HIV infectious disease, hepatitis C virus infection | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT00000694 | ? → Aug 1992 | HIV infectious disease, Kaposi's sarcoma | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1/29 trials | ||||||
| Phase 1/2 | NCT04988217 | Sep 2021 → Apr 2022 | COVID-19 | Pontificia Universidad Catolica de Chile | Completed | No outcome recorded |
| Phase 1/2 | NCT02151448 | Jul 2014 → Feb 2019 | malignant pancreatic neoplasm, malignant peritoneal mesothelioma, peritoneal carcinomatosis | David Bartlett | Completed | No outcome recorded |
| Phase 1/2 | NCT01409187 | Oct 2011 → Oct 2016 | melanoma | M.D. Anderson Cancer Center | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT01639885 | Aug 2011 → Jan 2014 | ovarian cancer | Leiden University Medical Center | Completed | No outcome recorded |
| Phase 1/2 | NCT01637532 | Feb 2011 → Sep 2013 | ovarian cancer | Leiden University Medical Center | Completed | No outcome recorded |
| Phase 1/2 | NCT00030342 | Nov 2001 → Oct 2007 | colorectal cancer, kidney cancer | St. Luke's Medical Center | Completed | No outcome recorded |
| Phase 1/2 | NCT00059358 | Sep 2001 → Jun 2005 | HIV infectious disease, hepatitis C virus infection | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1/2 | NCT00234182 | Jan 2000 → Dec 2004 | hepatocellular carcinoma | The University of Hong Kong | Completed | No outcome recorded |
| Phase 1/2 | NCT00003585 | Aug 1996 → Aug 2001 | kidney cancer | University of New Mexico | Completed | No outcome recorded |
| Phase 226 trials · 1 met primary | ||||||
| Phase 2 | NCT01658813 | Jul 2012 → Jul 2014 | digestive system cancer, non-small cell lung carcinoma, renal cell carcinoma | Western Regional Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT00963664 | Dec 2009 → Dec 2016 | melanoma | NeoPlas Innovation | Withdrawn | No outcome recorded |
| Phase 2 | NCT01100528 | Nov 2009 → Jul 2015 | iris melanoma, medium/large size posterior uveal melanoma, small size posterior uveal melanoma | Case Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00919633 | Jun 2009 → Jul 2012 | hepatitis C virus infection | Medtronic Corporate Technologies and New Ventures | Completed | No outcome recorded |
| Phase 2 | NCT00863239 | Mar 2009 → Nov 2010 | chronic hepatitis C virus infection | Biolex Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00913913 | Feb 2009 → Jan 2013 | renal cell carcinoma | Dartmouth-Hitchcock Medical Center | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00561912 | Oct 2007 → Nov 2009 | renal cell carcinoma | M.D. Anderson Cancer Center | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00505635 | Mar 2007 → Apr 2010 | melanoma | M.D. Anderson Cancer Center | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00471484 | Mar 2007 → ? | liver cancer | National Cancer Centre, Singapore | Unknown | No outcome recorded |
| Phase 2 | NCT00610857 | Nov 2006 → Jan 2015 | melanoma | Ahmad Tarhini | Completed | No outcome recorded |
| Phase 2 | NCT00126594 | Jun 2005 → Aug 2013 | clear cell renal carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00059826 | Mar 2003 → Jul 2007 | pancreatic adenocarcinoma | Alliance for Clinical Trials in Oncology | Completed | Met primary |
| Phase 2 | NCT00176527 | Nov 2002 → Aug 2007 | prostate cancer | University of Medicine and Dentistry of New Jersey | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00026143 | Oct 2001 → Jul 2004 | melanoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00030849 | Oct 2001 → Sep 2004 | lymphoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00138151 | Mar 2001 → Nov 2010 | cervical cancer | University of Medicine and Dentistry of New Jersey | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00006384 | Nov 2000 → Feb 2007 | kidney cancer | City of Hope Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT00006385 | Sep 2000 → Oct 2006 | cutaneous melanoma | Eastern Cooperative Oncology Group | Completed | No outcome recorded |
| Phase 2 | NCT00003656 | Jan 1999 → May 2008 | kidney cancer | Weill Medical College of Cornell University | Completed | No outcome recorded |
| Phase 2 | NCT00004040 | Jun 1998 → Jun 1999 | leukemia, plasma cell neoplasm | Hoag Memorial Hospital Presbyterian | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00004104 | Jun 1998 → Jul 2000 | cutaneous melanoma | NYU Langone Health | Completed | No outcome recorded |
| Phase 2 | NCT00003007 | Jul 1996 → Jan 2004 | plasma cell myeloma | University of Tennessee | Completed | No outcome recorded |
| Phase 2 | NCT00003091 | Jan 1996 → Jan 2000 | cutaneous melanoma, kidney cancer | Hoag Memorial Hospital Presbyterian | Completed | No outcome recorded |
| Phase 2 | NCT00001379 | May 1995 → Jan 2025 | lymphomatoid granulomatosis, lymphoproliferative syndrome | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00001114 | ? → Mar 2000 | HIV infectious disease, Kaposi's sarcoma | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2 | NCT00293527 | ? → Nov 2006 | kidney cancer | Ohio State University Comprehensive Cancer Center | Withdrawn | No outcome recorded |
| Phase 2/34 trials · 1 missed | ||||||
| Phase 2/3 | NCT04349410 | Apr → Sep 2020 | COVID-19 | The Camelot Foundation | Completed | No outcome recorded |
| Phase 2/3 | NCT00624325 | Jul 2007 → Jun 2010 | chronic hepatitis C virus infection | Foundation for Liver Research | Completed | No outcome recorded |
| Phase 2/3 | NCT03547154 | Oct 1998 → Feb 2001 | chronic myeloid leukemia | Merck Sharp & Dohme LLC | Terminated | Missed primary |
| Phase 2/3 | NCT03552549 | Aug 1998 → Feb 2001 | melanoma | Merck Sharp & Dohme LLC | Terminated | No outcome recorded Stop: Enrollment |
| Phase 313 trials · 8 missed | ||||||
| Phase 3 | NCT01463592 | Jun 2010 → Jun 2013 | chronic hepatitis C virus infection | MTI Medical Private Limited, Pakistan | Unknown | No outcome recorded |
| Phase 3 | NCT00569127 | Dec 2007 → Jan 2015 overdue | colorectal neuroendocrine tumor G1, gastric neuroendocrine tumor G1 | National Cancer Institute (NCI) | Active not recruiting | Missed primary |
| Phase 3 | NCT00226408 | Nov 2003 → Sep 2005 | melanoma | Dermatologic Cooperative Oncology Group | Unknown | Missed primary |
| Phase 3 | NCT01359956 | Apr 2002 → Feb 2011 | melanoma | National Cancer Institute, Naples | Completed | Missed primary |
| Phase 3 | NCT00125814 | Dec 2001 → Jan 2005 | HIV infectious disease | French National Agency for Research on AIDS and Viral Hepatitis | Terminated | No outcome recorded |
| Phase 3 | NCT00560053 | Jan 2000 → Feb 2005 | plasma cell myeloma | PETHEMA Foundation | Completed | No outcome recorded |
| Phase 3 | NCT00003444 | Mar 1999 → Sep 2003 | cutaneous melanoma | Eastern Cooperative Oncology Group | Completed | No outcome recorded |
| Phase 3 | NCT00003641 | Mar 1999 → Jan 2015 | cutaneous melanoma | ECOG-ACRIN Cancer Research Group | Completed | Missed primary |
| Phase 3 | NCT00273247 | Jun 1998 → Sep 2005 | cirrhosis of liver, hepatitis C virus infection, hepatocellular carcinoma, interferon antiviral depressor | National Cancer Institute, Milan | Completed | Missed primary |
| Phase 3 | NCT00149565 | Oct 1997 → Jul 2005 | hepatocellular carcinoma | National Health Research Institutes, Taiwan | Completed | Missed primary |
| Phase 3 | NCT01259934 | Nov 1996 → Jun 2008 | cutaneous melanoma | Karolinska Institutet | Completed | Missed primary |
| Phase 3 | NCT00002763 | Apr 1996 → ? | cutaneous melanoma | European Organisation for Research and Treatment of Cancer - EORTC | Unknown | Missed primary |
| Phase 3 | NCT00686478 | — | — | University of Alberta | Withdrawn | No outcome recorded |
| Phase 43 trials | ||||||
| Phase 4 | NCT02027064 | Oct 2013 → Oct 2017 | acute myeloid leukemia | Peking University People's Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT02360592 | Jun 2013 → Dec 2016 | chronic hepatitis B virus infection | Tongji Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00854581 | Nov 2007 → Jun 2011 | lymphoma, precancerous condition | University of Miami | Terminated | No outcome recorded |
| Phase not applicable3 trials | ||||||
| — | NCT02185261 | Jun 2014 → Jun 2021 | leukemia | Peking University People's Hospital | Unknown | No outcome recorded |
| — | NCT01192698 | Oct 2009 → Feb 2013 | cirrhosis of liver, hepatitis C virus infection | Wake Forest University Health Sciences | Completed | No outcome recorded |
| — | NCT00002270 | — | HIV infectious disease, progressive multifocal leukoencephalopathy | University of Miami | Completed | No outcome recorded |
| Comparator or background therapy22 trials | ||||||
| Phase 1 | NCT01603212 Background | Jul 2013 → Jul 2017 | melanoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT01608594 Background | May 2013 → Feb 2017 | melanoma | Diwakar Davar | Completed | No outcome recorded |
| Phase 1 | NCT01409174 Background | Feb 2013 → May 2016 | melanoma | M.D. Anderson Cancer Center | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT00311558 Background | Oct 2005 → May 2011 | cancer | The Cleveland Clinic | Terminated | No outcome recorded |
| Phase 1/2 | NCT03066947 Background | May 2017 → Nov 2018 | breast cancer | BriaCell Therapeutics Corporation | Completed | No outcome recorded |
| Phase 2 | NCT02737046 Background | Dec 2016 → Dec 2024 | adult T-cell leukemia/lymphoma | University of Miami | Completed | No outcome recorded |
| Phase 2 | NCT01274273 Comparator | Oct 2009 → Dec 2015 | renal cell carcinoma | University of Aarhus | Unknown | Missed primary |
| Phase 2 | NCT00613509 Comparator | Jun 2008 → Apr 2010 | cancer, melanoma | Sanofi Pasteur, a Sanofi Company | Terminated | Missed primary Stop: Enrollment |
| Phase 2/3 | NCT01729663 Comparator | Apr 2009 → Dec 2018 | cutaneous melanoma | Laboratorio Pablo Cassará S.R.L. | Unknown | No outcome recorded |
| Phase 2/3 | NCT00275938 Background | Oct 1998 → Jun 2001 | chronic hepatitis B virus infection | National Taiwan University Hospital | Completed | No outcome recorded |
| Phase 2/3 | NCT03537274 Comparator | Aug 1997 → Jul 1999 | chronic hepatitis C virus infection | Merck Sharp & Dohme LLC | Completed | Mixed |
| Phase 2/3 | NCT00538811 Background | — | hepatitis C virus infection | Aga Khan University | Completed | No outcome recorded |
| Phase 3 | NCT01860742 Comparator | Dec 2014 → Oct 2016 | digestive system neuroendocrine neoplasm | Jules Bordet Institute | Withdrawn | No outcome recorded |
| Phase 3 | NCT03435302 Comparator | Feb 2014 → Feb 2018 | melanoma | Peking University Cancer Hospital & Institute | Unknown | No outcome recorded |
| Phase 3 | NCT00647465 Comparator | Oct 2005 → May 2006 | influenza | Assistance Publique - Hôpitaux de Paris | Terminated | No outcome recorded |
| Phase 3 | NCT00221702 Comparator | Jun 2003 → Oct 2010 | cutaneous melanoma, metastatic neoplasm | University Hospital, Bordeaux | Completed | Missed primary |
| Phase 3 | NCT00005966 Background | Oct 2000 → Mar 2006 | renal cell carcinoma | Eastern Cooperative Oncology Group | Completed | No outcome recorded |
| Phase 3 | NCT00083551 Comparator | Aug 1998 → Aug 2014 | plasma cell myeloma | University of Arkansas | Completed | No outcome recorded |
| Phase 4 | NCT02323659 Comparator | Jun 2014 → Mar 2018 | mycosis fungoides | Polish Lymphoma Research Group | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT02199327 Comparator | May 2014 → Dec 2016 | conjunctival intraepithelial neoplasm, corneal intraepithelial neoplasm | Coordinación de Investigación en Salud, Mexico | Completed | No outcome recorded |
| Phase 4 | NCT00375661 Comparator | Sep 2006 → Mar 2012 | chronic hepatitis C virus infection | Kyoto University | Completed | No outcome recorded |
| — | NCT02454764 Comparator | ? → Jan 2018 | hepatitis B virus infection | Institute of Liver and Biliary Sciences, India | Withdrawn | No outcome recorded Stop: Business |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2025-08-04 | Ainos, Inc. (f/k/a Amarillo Biosciences Inc. | Regulatory Ainos Receives TFDA Approval to Initiate Clinical Study of VELDONA for Primary Sjögren's Syndrome ainos.com ↗ |
| 2025-05-19 | Ainos, Inc. (f/k/a Amarillo Biosciences Inc. | Results Ainos Reports Breakthrough Interim Results in VELDONA Clinical Trial for FCGS, Signaling New Era in Companion Animal Immunotherapy ainos.com ↗
The interim results demonstrate meaningful improvements in inflammation and a consistent reduction in steroid dependency, indicating strong commercial and scientific potential for a novel class of immunotherapy in companion animals. |
| 2024-02-05 | Ainos, Inc. (f/k/a Amarillo Biosciences Inc. | Regulatory Ainos Submits Clinical Hold Complete Response to US FDA to Resolve the Deficiencies on Investigational New Drug Phase II Trial of its VELDONA Formulation Against Mild COVID-19 Symptoms ainos.com ↗
today announced that it has submitted the clinical hold complete response to the U.S. Food and Drug Administration (the "U.S. FDA") for conducting a Phase II trial of its low-dose oral interferon (IFN)-alpha formulation, VELDONA®, for treatment of mild COVID-19 symptoms. |
| 2012-11-11 | Bristol-Myers Squibb | Results Investigational Hepatitis C Quad Therapy Regimen of Daclatasvir and Asunaprevir Plus Interferon Alfa and Ribavirin Achieved SVR24 in 93% of Difficult-to-Treat Genotype 1a/b Prior Null Responders in Expanded Phase II Study bms.com ↗ |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-08-04 | Ainos, Inc. (f/k/a Amarillo Biosciences Inc. | Ainos Receives TFDA Approval to Initiate Clinical Study of VELDONA for Primary Sjögren's Syndrome ainos.com ↗ |
| 2025-05-19 | Ainos, Inc. (f/k/a Amarillo Biosciences Inc. | Ainos Reports Breakthrough Interim Results in VELDONA Clinical Trial for FCGS, Signaling New Era in Companion Animal Immunotherapy ainos.com ↗ |
| 2024-02-05 | Ainos, Inc. (f/k/a Amarillo Biosciences Inc. | Ainos Submits Clinical Hold Complete Response to US FDA to Resolve the Deficiencies on Investigational New Drug Phase II Trial of its VELDONA Formulation Against Mild COVID-19 Symptoms ainos.com ↗ |
| 2012-11-11 | Bristol-Myers Squibb | Investigational Hepatitis C Quad Therapy Regimen of Daclatasvir and Asunaprevir Plus Interferon Alfa and Ribavirin Achieved SVR24 in 93% of Difficult-to-Treat Genotype 1a/b Prior Null Responders in Expanded Phase II Study bms.com ↗ |
Evidence & citations 25 cited values
Every value below carries the sentence it was read from. 104 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | interferon alfa-2b | “The goal of the Phase I part of this clinical research study is to find the highest tolerable dose of the drug Yervoy (ipilimumab) that can be given with the drugs Intron-A...” NCT01409187 ↗63“OBJECTIVES: I. Evaluate the toxic effects, patient tolerance, and practicality of administering interferon alfa-2b, fluorouracil, interleukin-2, and isotretinoin (FUNIL-cRa) in...” NCT00003585 ↗ “The hypothesis is that patients who receive ribavirin immediately before transplant and intravenous interferon alfa 2b during the anhepatic phase(while the liver is...” NCT01192698 ↗ “If a complete response was not seen after 8 weeks, interferon alfa-2b 3 million units (MU) subcutaneously was added, and increased to 5 MU if tolerated, 3 times a week.” PMID 17366595 ↗ May 2007 “patients with low-grade disease received dose-escalated interferon alfa-2b, starting at 7·5 million international units subcutaneously three times per week” PMID 37011643 ↗ Mar 2023 “Patients receive tretinoin liposome IV over 30 minutes once weekly and interferon alfa-2b subcutaneously on five consecutive days (M-F) for 8 weeks.” NCT00003656 ↗ “Interferon alfa-2b (IFN-A) maintenance is administered 3 times per week following bone marrow recovery from the first or second L-PAM courses.” NCT00003007 ↗ “Patients assigned to arms II or III also receive interferon alfa-2b subcutaneously, at one of two doses, three times a week for 2 years.” NCT00004104 ↗ “Phase II Trial of Interleukin-12 (NSC #672423, IND #6798) Followed by Interferon Alfa-2B in Patients With Metastatic Malignant Melanoma” NCT00026143 ↗ “Patients receive fluorouracil IV over 24 hours on day 6 of week 2 and interferon alfa-2b SC and GM-CSF SC 3 times weekly on weeks 3-5.” NCT00030342 ↗ “Patients receive subcutaneous interferon alfa-2b every other day three times per week for 12 months.” NCT00004040 ↗ |
| Known as | HDI | “We hypothesized that neoadjuvant ipilimumab in combination with high dose IFNα2b (HDI) is safe and associated with durable pathologic complete responses (pCR).” PMID 30352626 ↗ Oct 20181“Pembrolizumab and high dose interferon alfa-2b (HDI)” NCT02339324 ↗ |
| Known as | Human Serum Albumin/interferon alpha2b | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02781753 ↗ |
| Known as | IFN | “outpatient subcutaneous (s.c.) interferon-alpha2b (IFN), followed by an inpatient hybrid schedule” PMID 16706633 ↗ Apr 2006 |
| Known as | IFN alfa-2b | “To investigate the toxicity of interferon alfa-2b ( IFN alfa-2b ) in combination with nucleoside analog therapy in HIV-positive patients with chronic hepatitis C.” NCT00001035 ↗1“Neoadjuvant Combination Biotherapy With Pembrolizumab and High Dose IFN-alfa2b” NCT02339324 ↗ |
| Known as | IFN-A | “Interferon alfa-2b (IFN-A) maintenance is administered 3 times per week following bone marrow recovery from the first or second L-PAM courses.” NCT00003007 ↗1“Arm A: Biological Response Modifier Therapy. Interferon alfa-2b (Schering), IFN-A, NSC-377523.” NCT00002763 ↗ |
| Known as | IFN-A2b | “sargramostim ( granulocyte-macrophage colony-stimulating factor; GM-CSF ), interferon alfa-2b ( IFN-A2b ), and zidovudine ( AZT )” NCT00000694 ↗3“three subcutaneous injections of IFNa-2b (6 MiU, Schering -Plough Corp.)” NCT00913913 ↗ “Recombinant Alpha Interferon (IFN-A2b)” NCT00002270 ↗ |
| Known as | IFN-alpha | “interferon alpha-2b (IFN-alpha) and ribavirin plus either” PMID 22755276 ↗ Apr 2012 |
| Known as | IFN-alpha2b | “IFN-alpha2b (Intron A; Schering-Plough) 10 million units/m2 three times a week” PMID 19228745 ↗ Feb 2009 |
| Known as | IFN-α | “Interferon alpha-2B (IFN-α) 3 million units (MU) subcutaneous daily” NCT02331706 ↗ |
| Known as | IFN-α-2b | “Patients with stage III resected lymph node or in-transit metastasis from cutaneous malignant melanoma were randomly assigned to receive either a standard HDI regimen or three...” PMID 26503196 ↗ Oct 20159“Patients were randomly assigned to treatment with octreotide LAR 20 mg every 21 days with either bevacizumab 15 mg/kg every 21 days or 5 million units of IFN-α-2b three times per week.” PMID 28384065 ↗ Apr 2017 “Subcutaneous injections of recombinant human IFN-α-2b were performed for 6 cycles, and prolonged IFN-α therapy could be permitted at the request of patients.” PMID 35154096 ↗ Jan 2022 “Neoadjuvant ipilimumab (3 mg/kg or 10 mg/kg) and high dose IFN-α2b in locally/regionally advanced melanoma: safety, efficacy and impact on T-cell repertoire.” PMID 30352626 ↗ Oct 2018 “Subcutaneous injections of recombinant human IFN-α-2b were performed for 6 cycles, and prolonged IFN-α therapy could be permitted at the request of patients.” PMID 35154096 ↗ Jan 2022 “IFN-α-2b was administered at 3 million units three times a week subcutaneously for 24 weeks” PMID 31371315 ↗ Aug 2019 “adjuvant interferon alfa-2b (IFNα-2b) therapy” PMID 22104564 ↗ Jan 2012 “Interferon-α-2b (IFNα-2b)” NCT00913913 ↗ |
| Known as | INFα 2b | “Among the drugs used the investigators have mitomycin C (MMC) and interferon alpha 2b (INFα 2b).” NCT02199327 ↗ |
| Known as | Interferon alpha-2b | “The study protocol is being conducted to compare intermittent high-dose i.v. administation of interferon alpha-2b with the standard high-dose treatment by Kirkwood” NCT00226408 ↗28“We conducted an adjuvant trial of sequential, low-dose dacarbazine (DTIC) and interferon-alpha-2b (IFN-α-2b)” PMID 31371315 ↗ Aug 2019 “Among the drugs used the investigators have mitomycin C (MMC) and interferon alpha 2b (INFα 2b).” NCT02199327 ↗ “INTERFERON ALPHA 2b 3 Million Units s/c +RIBAVIRIN 15mg/kg” NCT01463592 ↗ “Interferon alpha-2b 5 million units per nebulizer BID.” NCT04349410 ↗ |
| Known as | Interferon-α-2b | “Interferon-α-2b (IFNα-2b)” NCT00913913 ↗ |
| Known as | Intron A | “The study was originally designed for lymphoblastoid α-interferon; then soon after trial approval by the NCI-Milan Scientific and Ethic Committee (#98-016) the protocol was...” NCT00273247 ↗12“1 million IU of interferon alpha 2b (Intron A) subcutaneously once a day for 7 days, then 3 million IU of interferon alpha 2b (Intron A) subcutaneously three times a week for 23 weeks.” NCT00686478 ↗ “IFN-alpha2b (Intron A; Schering-Plough) 10 million units/m2 three times a week” PMID 19228745 ↗ Feb 2009 “interferon alfa-2b (Intron-A, Schering-Plough, Kenilworth, NJ)” PMID 17366595 ↗ May 2007 “SC interferon alpha 2b (Introna®) 0.9 million IU x 3/week.” NCT00908869 ↗ “I = IFN-α-2b (INTRON A): 5 million units (MU)/m2 SC.” NCT01462773 ↗ “IntronA 3miu TIWW SC for 18 months” NCT00221702 ↗ “low dose IFN-alpha 2B (Intron-A)” PMID 14581348 ↗ Oct 2003 “Intron A, Interferon alpha -2b” NCT00613509 ↗ “Interferon Alpha-2b (Intron A)” NCT00293527 ↗ “Drug: intron A” NCT00221702 ↗ |
| Known as | Intron-A: IFN-α2b | “Intron-A®: IFN-α2b” NCT00613509 ↗ |
| Known as | Locteron | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00863239 ↗ |
| Known as | NSC-377523 | “Arm A: Biological Response Modifier Therapy. Interferon alfa-2b (Schering), IFN-A, NSC-377523.” NCT00002763 ↗ |
| Known as | Peg-Intron | “Chemo-Immunotherapy, Gemcitabine With Pegylated Interferon Alpha-2b (Peg-Intron) With and Without p53 Synthetic Long Peptide (p53 SLP) Vaccine, for Patients With Platinum...” NCT01639885 ↗1“immune enhancer interferon-α (Peg-Intron)” PMID 26216383 ↗ Jul 2015 |
| Known as | recombinant human interferon α-2b | “recombinant human interferon α-2b” NCT07635459 ↗ |
| Known as | Recombinant Human Serum Albumin/interferon alpha2b Fusion Protein | “characterize the PK/PD profile, safety and tolerability of Recombinant Human Serum Albumin/interferon alpha2b Fusion Protein in healthy subjects.” NCT02781753 ↗ |
| Known as | Recombinant Interferon Alfa-2b | “Biological: Recombinant Interferon Alfa-2b” NCT00126594 ↗ |
| Action | Inhibit | “IFN alfa-2b has HIV inhibitory properties” NCT00001035 ↗ |
| Modality | Protein / enzyme biologic | “Recombinant Alpha Interferon” NCT00000694 ↗ |
| Route | Subcutaneous | “IFN-A2b and GM-CSF are given in two separate injections under the skin (subcutaneous injection) once a day” NCT00000694 ↗ |